News

The European Medicines Agency welcomes the political agreement on modernized EU pharmaceutical legislation, enhancing medicine development, authorization, supply security, and innovation through new rules on shortages and regulatory sandboxes.

SCIEX has begun localized production and support of its XR QTOF and ZenoTOF mass spectrometry systems in China, enhancing access to advanced analytical equipment for Asian biopharma R&D and QC labs.

EU institutions have reached a political agreement on a comprehensive overhaul of pharmaceutical legislation aimed at boosting innovation, speeding approvals and improving supply security across Europe, with significant regulatory and market implications for drug developers and manufacturers.

China’s biopharma industry enters 2026 with record outbound licensing value, robust Hong Kong IPO and capital-market activity, and policy moves to fast-track innovative drugs and dual insurance coverage, reshaping strategic priorities for Asian pharma executives and investors.

The European Pharmacopoeia has reached a key milestone in phasing out animal-based endotoxin testing, pushing European pharmaceutical manufacturers to adopt advanced in vitro alternatives in their quality control strategies from 2026.

Hisamitsu Pharmaceutical's founding family member and CEO Kazuhide Nakatomi is negotiating a management buyout of the Japanese firm at a $2.9 billion valuation.

Esco Aster, a Singapore-based CRDMO, has signed a clinical cGMP manufacturing contract with Shine-On Biomedical for an innovative HLA-G targeting exosome drug delivery platform.[7]

Clarivate's annual Drugs to Watch report, released today from London, identifies eleven innovative therapies with blockbuster potential in metabolic disease, oncology, immunology, and more, leveraging AI-powered intelligence for pharmaceutical R&D strategy.

HUTCHMED has initiated the Phase III part of its trial evaluating surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma in China.

Vietnam's pharmaceutical exports reached $312 million last year, ranking fourth in Southeast Asia, driven by improved production capacities, GMP-compliant factories, and ongoing regulatory digital transformation.